Vitamin K2 (MK-7): The Calcium Traffic Controller

Swallow a calcium supplement and you've made a decision without realising it: that calcium will either reinforce your skeleton or harden your arteries. The molecule is identical. What differs is routing — and the protein switches that do the routing only work when a specific, under-appreciated vitamin activates them. That vitamin is K2.

The Two Proteins That Decide Everything

Vitamin K2 has one biochemical job with two consequences. It carboxylates (activates) a small set of calcium-binding proteins, two of which matter here:

• Osteocalcin — made by bone-building osteoblasts, it binds calcium into the bone matrix. Activated osteocalcin is bone construction; its inactive form is a marker of functional K deficiency.
• Matrix Gla protein (MGP) — the body's most potent natural inhibitor of vascular calcification. Active MGP patrols the arterial wall and prevents calcium from depositing there. Inactive MGP lets it accumulate.

So the same vitamin simultaneously tells calcium "go into bone" and "stay out of arteries." When K2 is scarce, both instructions weaken at once — the mechanistic heart of what's often called the calcium paradox: supplementing calcium without the machinery to direct it can strengthen bone and stiffen arteries in the same person.

Why MK-7 Specifically

Not all vitamin K is equal. K1 (from leafy greens) is claimed almost entirely by the liver for blood clotting and barely reaches bone or vasculature. Among the K2 menaquinones, MK-7 has a far longer circulating half-life than MK-4 — which means a single daily dose actually stays in the blood long enough to reach the extrahepatic tissues where osteocalcin and MGP live. That pharmacokinetic detail is why nearly all the good supplement trials use MK-7.

What the Trials Show

This is where K2 earns an authority claim rather than a mechanistic hope:

• A 3-year randomised trial of 180 mcg/day MK-7 in 244 healthy postmenopausal women slowed the loss of bone mineral density at both the lumbar spine and femoral neck versus placebo, and improved markers of osteocalcin activation. ^[2]
• A parallel 3-year MK-7 trial in the same population improved arterial stiffness, measured by carotid–femoral pulse-wave velocity — the stiffer-artery participants benefited most. ^[1] Moving a hard vascular stiffness marker with a supplement over three years is genuinely uncommon.
• An earlier vitamin K supplementation trial tracking coronary artery calcium progression in older adults pointed the same direction, supporting the calcification-inhibition mechanism even as the evidence for hard cardiac endpoints keeps maturing. ^[3]

Taken together, this is why we grade K2 at B: the bone and arterial-stiffness RCTs are real and multi-year, but the chain to hard cardiovascular events (heart attacks, not just calcium scores) is not yet closed.

Dosing

• 100–200 mcg/day of MK-7 is the evidence-backed range; the pivotal trials used 180 mcg.
• Take it with a fatty meal — it's fat-soluble — and ideally alongside vitamin D3, which shares the same meal and the same calcium story.
• There is no established toxicity threshold, and because K2 routes calcium rather than increasing its absorption, it carries no hypercalcaemia risk.

The Vitamin D3 Connection

Vitamin D3 is the reason K2 matters more than ever. D3 increases how much calcium you absorb — but it has no say in the destination. Push absorption up with high-dose D3 and leave K2 inadequate, and you've raised the supply of calcium without reinforcing the system that keeps it out of arterial walls. That is the theoretical basis for pairing them, and the logic behind the Bone & Arterial Longevity protocol: D3 opens the door, K2 directs the traffic. The dosing side of D3 is covered in Vitamin D Dosing: Why Most People Get It Wrong.

The Warfarin Warning — Non-Negotiable

K2 is one of the safest supplements available, with a single major exception that is absolute: warfarin and other vitamin-K-antagonist anticoagulants. These drugs work by blocking vitamin K. Adding K2 directly counteracts them and can destabilise INR, with real clotting consequences. If you take warfarin, do not add K2 unless your prescriber is actively managing it. Note this does not apply to DOACs such as apixaban or rivaroxaban, which have a different mechanism.

Bottom Line

Vitamin K2 doesn't build bone or clean arteries by brute force — it switches on the proteins that route calcium to the right place. On the strength of multi-year MK-7 trials, 100–200 mcg daily with a fatty meal is a well-evidenced, low-risk addition for most adults — provided you're not on warfarin, and provided you take it as part of the D3-anchored system it was meant to complete.

Related Reading

• Vitamin D Dosing: Why Most People Get It Wrong
• The Bone & Arterial Health Stack: D3 + K2 + Magnesium + Boron
• Boron: Testosterone, Bone Health & Vitamin D Activation